Long Term Follow-up of Children in the HIVNET 012 Perinatal HIV Prevention Trial: Five-Year Growth and Survival

Simple item page
dc.contributor.authorOwor, Maxensia
dc.contributor.authorMwatha, Anthony
dc.contributor.authorDonnell, Deborah
dc.contributor.authorMusoke, Philippa
dc.contributor.authorMmiro, Francis
dc.contributor.authorAllen, Melissa
dc.contributor.authorJackson, J. Brooks
dc.contributor.authorFowler, Mary Glenn
dc.contributor.authorLaura A
dc.contributor.authorGuay, Laura A.
dc.date.accessioned2022-01-31T14:41:18Z
dc.date.available2022-01-31T14:41:18Z
dc.date.issued2013
dc.description.abstractTo describe five year growth, survival and long-term safety among children exposed to nevirapine or zidovudine in an African perinatal prevention trial, HIVNET 012.All study children who were alive at eighteen months of age were eligible for an extended follow-up study. Children whose families consented were enrolled and evaluated every six months from 24 to 60 months. At each visit, history, physical exam and growth measures were taken. From these measurements Z scores based on World Health Organization (WHO) standards were computed. Serious adverse event data were collected. Data from the initial and extended follow-up cohorts were included in the analysis.528 study children were alive at age 18 months, and 491 (426 HIV uninfected; 65 infected) were enrolled into the follow-up study. Both exposed but uninfected children and HIV infected children were substantially below WHO growth standards for weight and height. Head circumference Z scores for uninfected children were comparable to WHO norms. Five-year survival rates were 93% for uninfected children versus 43% for infected children. Long-term safety and growth outcomes in the two study arms were similar.Both infected and uninfected children in the five-year HIVNET 012 follow-up showed poor height and weight growth outcomes, underscoring the need for early nutritional interventions to improve long-term growth of all infants born to HIV-infected women in resource limited settings. Likewise, the low five year survival among HIV infected children support the importance of early initiation of antiretroviral therapy. Both peripartum nevirapine and zidovudine were safe.en_US
dc.identifier.citationOwor, M., Mwatha, A., Donnell, D., Musoke, P., Mmiro, F., Allen, M., ... & Guay, L. A. (2013). Long Term Follow-up of Children in the HIVNET 012 Perinatal HIV Prevention Trial: Five-Year Growth and Survival. Journal of acquired immune deficiency syndromes (1999), 64(5), 464.doi: 10.1097/QAI.0000000000000015en_US
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1684
dc.language.isoenen_US
dc.publisherJournal of acquired immune deficiency syndromesen_US
dc.titleLong Term Follow-up of Children in the HIVNET 012 Perinatal HIV Prevention Trial: Five-Year Growth and Survivalen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Long Term Follow-up of Children in the HIVNET 012 Perinatal HIV Prevention Trial Five-Year Growth and Survival.pdf
Size:
620.95 KB
Format:
Adobe Portable Document Format
Description:
Long Term Follow-up of Children in the HIVNET 012 Perinatal HIV Prevention Trial: Five-Year Growth and Survival
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences